Results

1–10 of 89 results for DME

Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials
Dante Joseph Pieramici, MD
Annual Meeting Talks
2025
Efficacy and Safety Outcomes Over 12 Weeks With OCS-01 Eye Drops in DME From DIAMOND-Stage 1 Trial:Focus on Subgroup by Prior Treatment Status
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2025
Impact of PDS in Study Eyes vs Anti-VEGF Injections in Fellow Eyes in Pagoda Trial Patients With BilateralDiabetic Macular Edema (DME)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2025
PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2025
Update on Faricimab for DME: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2025
Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the United States
Andres Emanuelli, MD
Annual Meeting Talks
2025
Port Delivery System with Ranibizumab PDS for Continuous Treatment in DME and DR Additional Results from the Phase 3 Pagoda and Pavilion Trials
Dennis M. Marcus, MD
Annual Meeting Talks
2023
Early Treatment Patterns and Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: FARETINA-DME Study
Durga Borkar, MD
Annual Meeting Talks
2023
Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023
Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME
Rajeev H. Muni, MD, MSC, FRCS(C), FASRS
Annual Meeting Talks
2023